A Phase 1 study of the highly-selective RET Inhibitor, BLU-667, in patients with thyroid cancer, non-small cell lung cancer (NSCLC) and other advanced solid tumors

Cancer - Anus, Cancer - Bladder, Cancer - Bones and Joints, Cancer - Brain and Nervous System, Cancer - Breast, Cancer - Cervix Uteri, Cancer - Colon, Cancer - Corpus Uteri, Cancer - Esophagus, Cancer - Eye and Orbit, Cancer - Hodgkin's Lymphoma, Cancer - Ill-Defined Sites, Cancer - Kaposi's sarcoma, Cancer - Kidney, Cancer - Larynx, Cancer - Lip, Oral Cavity and Pharynx, Cancer - Liver, Cancer - Lung, Cancer - Melanoma, skin, Cancer - Mycosis Fungoides, Cancer - Non-Hodgkin's Lymphoma, Cancer - Other Digestive Organ, Cancer - Other Endocrine System, Cancer - Other Female Genital, Cancer - Other Male Genital, Cancer - Other Respiratory and Intrathoracic Organs, Cancer - Other Skin, Cancer - Other Urinary, Cancer - Ovary, Cancer - Pancreas, Cancer - Prostate, Cancer - Rectum, Cancer - Small Intestine, Cancer - Soft Tissue, Cancer - Stomach, Cancer - Thyroid, Cancer - Unknown Sites
Sai-Hong Ignatius Ou

For information about cancer clinical trials at the UCI Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.